Hers vs Oak Longevity: Which GLP-1 Provider Is Better?

By Iacob Pastina, Independent Researcher

53 providers verified independently·Independent research·How we rank →

Visit Oak Longevity - our pick of these two→or find your match

Oak Longevity beats Hers overall, scoring 7.5/10 vs 7.3/10. Oak Longevity is more affordable at $133/mo vs $199/mo. Choose Hers for women who want brand-name wegovy (injection or pill) at $149. Choose Oak Longevity for budget-conscious users who want one of the cheapest compound.

A side-by-side look at Hers and Oak Longevity to help you decide. We compare them on:

•Starting price per month
•Our overall score, out of 10
•Medication type, brand-name or compounded
•Whether they accept insurance
•Who each one is best for

Hers

#34 of 53

7.3/10

The women's health arm of Hims & Hers Health (NYSE: HIMS). In 2026 Hers signed a direct Novo Nordisk partnership adding FDA-approved Wegovy (pen and pill) at $149/mo and Zepbound via the Lilly partnership, alongside their existing compounded semaglutide and new compounded tirzepatide programs.

Visit Hers

Higher Rated

Oak Longevity

#25 of 53

7.5/10

Telehealth platform offering compounded semaglutide and tirzepatide at the lower end of market pricing, alongside an oral Wegovy option, brand-name FDA-approved GLP-1s, and a longevity stack (NAD+, Glutathione, Sermorelin, Tesamorelin). Distinctive non-subscription billing, patients pay each month manually rather than auto-renew.

Visit Oak Longevity

Feature	Hers	Oak Longevity
Our Score	7.3/10	7.5/10
Starting Price	$199/mo	$133/mo
Medication Type	Both	Both
Insurance Accepted	No	No
Best For	Women who want brand-name Wegovy (injection or pill) at $149/mo via the 2026 Novo Nordisk partnership, or a compounded semaglutide option from a publicly traded telehealth brand	Budget-conscious users who want one of the cheapest compounded GLP-1 entries plus a no-subscription billing model and a longevity-stack add-on (NAD+, Sermorelin)
Watch out for	Membership + medication are billed separately ($39 first month / $149 ongoing membership), so total both line items before comparing prices	Brand-name pricing ($1,200-$1,500/mo) is significantly above market, NovoCare sells Wegovy direct at $349/mo and LillyDirect has Zepbound at $299/mo. Use Oak for its compounded tiers and buy brand-name direct
Ranking	#34	#25
Get started	Visit Hers	Visit Oak Longevity

Pros & Cons Compared

Hers

Pros

+2026 Novo Nordisk partnership, FDA-approved Wegovy pen and Wegovy oral pill from $149/mo, one of the lowest brand-name GLP-1 prices on the market
+Zepbound access via the Lilly/Hims-Hers partnership announced 2026
+Publicly traded company (NYSE: HIMS) with strong financial backing and regulatory compliance
+Broader women's health platform, integrates weight loss with hormonal, skin, and wellness services

Cons

−Membership + medication are billed separately ($39 first month / $149 ongoing membership), so total both line items before comparing prices
−Support runs at big-platform scale, fine for routine refills, less personal if you want high-touch care
−Compounded pricing starts at $199/mo with stepped pricing at higher doses, budget for the dose you'll end up on, not the entry dose
−Zepbound access priced at ~$1,899/mo (brand cash) via the Lilly partnership, read as access, not value

Oak Longevity

Pros

+$133/mo for compounded semaglutide is among the cheapest entries on the market, Sesame Care ($99) is lower, but Oak undercuts most mid-tier platforms
+No-subscription model, patients are not auto-charged each month, choose to renew manually. Reduces unwanted recurring charges
+Compounded tirzepatide at $199/mo is competitively priced for a GLP-1+GIP dual agonist
+Broadest medication mix on the platform: compounded sema + tirz, oral Wegovy, brand Wegovy/Ozempic/Zepbound/Mounjaro, plus longevity peptides (NAD+, Glutathione, Sermorelin, Tesamorelin)
+Money-back guarantee if not approved by physician, useful safety net for borderline-eligibility patients
+Free shipping and free health coaching included in every program

Cons

−Brand-name pricing ($1,200-$1,500/mo) is significantly above market, NovoCare sells Wegovy direct at $349/mo and LillyDirect has Zepbound at $299/mo. Use Oak for its compounded tiers and buy brand-name direct
−No published lab panels and no specialty (obesity medicine) physicians disclosed, clinical oversight is lighter than lab-driven platforms
−The 'up to 50% cheaper than competitors' marketing claim is unverified and inconsistent, judge Oak on its posted prices, which are genuinely low, not on the slogan
−The longevity add-ons (NAD+, Sermorelin, Tesamorelin) have limited clinical evidence for weight loss specifically, if weight loss is the goal, the GLP-1 alone does the work and the stack is optional
−Newer brand without disclosed company history, founding date, or executive team on landing pages
−Three-month plans are billed upfront, start on the 1-month plan if you're testing the platform, then bundle once it fits

Our Verdict

Oak Longevity edges out Hers with a score of 7.5/10 vs 7.3/10. If budget is your priority, Oak Longevity starts at $133/mo compared to Hers's $199/mo. Choose Hers if you want: women who want brand-name wegovy (injection or pill) at $149/mo via the 2026 novo nordisk partnership, or a compounded semaglutide option from a publicly traded telehealth brand. Choose Oak Longevity if you want: budget-conscious users who want one of the cheapest compounded glp-1 entries plus a no-subscription billing model and a longevity-stack add-on (nad+, sermorelin).

Still undecided? Editor's Featured Pick

TrimRx

$149/mo · 7.8/10 · Compounded

If neither Hers nor Oak Longevity feels like the right fit, our featured pick across all 53 GLP-1 telehealth providers is TrimRx. It is not the highest-scored provider in our full rankings. We feature it for its low-friction value: a flat $149/mo that stays the same at every dose.

Visit TrimRx→Read our full TrimRx review